80 related articles for article (PubMed ID: 22130134)
1. 5-sulfonyl-benzimidazoles as selective CB2 agonists-part 2.
Gijsen HJ; De Cleyn MA; Surkyn M; Van Lommen GR; Verbist BM; Nijsen MJ; Meert T; Wauwe JV; Aerssens J
Bioorg Med Chem Lett; 2012 Jan; 22(1):547-52. PubMed ID: 22130134
[TBL] [Abstract][Full Text] [Related]
2. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887
[TBL] [Abstract][Full Text] [Related]
3. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.
Omura H; Kawai M; Shima A; Iwata Y; Ito F; Masuda T; Ohta A; Makita N; Omoto K; Sugimoto H; Kikuchi A; Iwata H; Ando K
Bioorg Med Chem Lett; 2008 Jun; 18(11):3310-4. PubMed ID: 18440813
[TBL] [Abstract][Full Text] [Related]
4. Benzimidazole CB2 agonists: design, synthesis and SAR.
Nanda KK; Henze DA; Della Penna K; Desai R; Leitl M; Lemaire W; White RB; Yeh S; Brouillette JN; Hartman GD; Bilodeau MT; Trotter BW
Bioorg Med Chem Lett; 2014 Feb; 24(4):1218-21. PubMed ID: 24461289
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
6. Novel benzimidazole derivatives as selective CB2 agonists.
Pagé D; Balaux E; Boisvert L; Liu Z; Milburn C; Tremblay M; Wei Z; Woo S; Luo X; Cheng YX; Yang H; Srivastava S; Zhou F; Brown W; Tomaszewski M; Walpole C; Hodzic L; St-Onge S; Godbout C; Salois D; Payza K
Bioorg Med Chem Lett; 2008 Jul; 18(13):3695-700. PubMed ID: 18522867
[TBL] [Abstract][Full Text] [Related]
7. Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain.
Brindisi M; Maramai S; Gemma S; Brogi S; Grillo A; Di Cesare Mannelli L; Gabellieri E; Lamponi S; Saponara S; Gorelli B; Tedesco D; Bonfiglio T; Landry C; Jung KM; Armirotti A; Luongo L; Ligresti A; Piscitelli F; Bertucci C; Dehouck MP; Campiani G; Maione S; Ghelardini C; Pittaluga A; Piomelli D; Di Marzo V; Butini S
J Med Chem; 2016 Mar; 59(6):2612-32. PubMed ID: 26888301
[TBL] [Abstract][Full Text] [Related]
8. Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.
Worm K; Zhou QJ; Saeui CT; Green RC; Cassel JA; Stabley GJ; DeHaven RN; Conway-James N; LaBuda CJ; Koblish M; Little PJ; Dolle RE
Bioorg Med Chem Lett; 2008 May; 18(9):2830-5. PubMed ID: 18430570
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
10. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
Watson C; Owen DR; Harding D; Kon-I K; Lewis ML; Mason HJ; Matsumizu M; Mukaiyama T; Rodriguez-Lens M; Shima A; Takeuchi M; Tran I; Young T
Bioorg Med Chem Lett; 2011 Jul; 21(14):4284-7. PubMed ID: 21669533
[TBL] [Abstract][Full Text] [Related]
11. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
[TBL] [Abstract][Full Text] [Related]
12. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
Lange JH; van der Neut MA; Wals HC; Kuil GD; Borst AJ; Mulder A; den Hartog AP; Zilaout H; Goutier W; van Stuivenberg HH; van Vliet BJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):1084-9. PubMed ID: 20031412
[TBL] [Abstract][Full Text] [Related]
14. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
15. Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.
Parks DJ; Parsons WH; Colburn RW; Meegalla SK; Ballentine SK; Illig CR; Qin N; Liu Y; Hutchinson TL; Lubin ML; Stone DJ; Baker JF; Schneider CR; Ma J; Damiano BP; Flores CM; Player MR
J Med Chem; 2011 Jan; 54(1):233-47. PubMed ID: 21128593
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
Raitio KH; Savinainen JR; Vepsäläinen J; Laitinen JT; Poso A; Järvinen T; Nevalainen T
J Med Chem; 2006 Mar; 49(6):2022-7. PubMed ID: 16539390
[TBL] [Abstract][Full Text] [Related]
17. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.
LaBuda CJ; Koblish M; Little PJ
Eur J Pharmacol; 2005 Dec; 527(1-3):172-4. PubMed ID: 16316653
[TBL] [Abstract][Full Text] [Related]
20. Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
Hollinshead SP; Tidwell MW; Palmer J; Guidetti R; Sanderson A; Johnson MP; Chambers MG; Oskins J; Stratford R; Astles PC
J Med Chem; 2013 Jul; 56(14):5722-33. PubMed ID: 23795771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
